FDA Approves Pfizer’s Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions
Pfizer, Inc. (NYSE:PFE) today announced the...
Read MorePfizer, Inc. (NYSE:PFE) today announced the...
Read MoreThe Union Health Ministry has...
Read MoreVertex Pharmaceuticals Incorporated (Nasdaq: VRTX)...
Read MoreNano cap Innovation Pharmaceuticals (OTCQB:IPIX...
Read MoreBased on new evidence assessing...
Read MoreThe Foundation for Innovative New...
Read MoreInSphero AG announced the launch...
Read MoreMore than 30 million Americans...
Read MoreBoehringer Ingelheim has signed a...
Read MoreTo enhance the health of...
Read More